Table 2.
Univariable Cox regression analysis for MACE in Patients with AMI.
Characteristic | HR (95% CI) | p-Value |
---|---|---|
Ages, years | 1.034 (1.016–1.051) | <0.001 |
Females, % | 2.168 (1.405–3.346) | <0.001 |
New AMI, % | 1.049 (0.600–1.837) | 0.866 |
Previous histories | ||
Stroke, % | 1.311 (0.712–2.417) | 0.385 |
Hypertension, % | 0.872 (0.568–1.341) | 0.534 |
Diabetes, % | 1.295 (0.811–2.068) | 0.279 |
Smoking, % | 0.535 (0.349–0.822) | 0.004 |
Systolic BP, mmHg | 1.001 (0.991–1.011) | 0.888 |
Diastolic BP, mmHg | 0.994 (0.979–1.010) | 0.473 |
Heart rate, beats/min | 1.008 (0.996–1.020) | 0.210 |
Creatinine, µmol/L | 1.000 (0.999–1.000) | 0.718 |
Total cholesterol, mmol/L | 0.993 (0.963–1.024) | 0.649 |
Low-density lipoprotein, mmol/L | 0.965 (0.781–1.193) | 0.745 |
High-density lipoprotein, mmol/L | 0.956 (0.800–1.142 | 0.618 |
Triglycerides, mmol/L | 0.892 (0.768–1.035) | 0.132 |
Fasting glucose, mmol/L | 1.036 (0.966–1.111) | 0.328 |
Cardiac Troponins I, μg/L | 1.000 (0.999–1.001) | 0.528 |
ST-segment elevation, % | 1.176 (0.766–1.805) | 0.460 |
Killip II/III class, % | 2.313 (1.323–4.044) | 0.003 |
PCI, % | 0.831 (0.523–1.320) | 0.432 |
Medical treatment | ||
Aspirin, % | 0.408 (0.178–0.937) | 0.034 |
Statin, % | 0.309 (0.149–0.641) | 0.002 |
Clopidogrel, % | 1.241 (0.768–2.005) | 0.377 |
Beta-blocker, % | 0.591 (0.385–0.908) | 0.016 |
Ticagrelor, % | 0.572 (0.336–0.975) | 0.040 |
ACEI/ARB, % | 0.814 (0.529–1.251) | 0.348 |
HR hazard ratio, CI confidence interval, MACE major adverse cardiac events, other abbreviations as in Table 1.